There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eiger Biopharmaceuticals (EIGR – Research Report) and Homology Medicines (FIXX – Research Report) with bullish sentiments. Eiger Biopharmaceuticals (EIGR) Robert W. Baird analyst Brian Skorney maintained a Buy rating on Eiger Biopharmaceuticals yesterday and set a price target of $29.00. The company's shares closed last Tuesday at $4.99. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-eiger-biopharmaceuticals-eigr-homology-medicines-fixx?utm_source=advfn.com&utm_medium=referral
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Homology Medicines Charts.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Homology Medicines Charts.